Clinical

ADA 2026 research showed how oral ketones, irisin, and SGLT2 inhibitors may reveal new metabolic pathways beyond glucose control.

Phase 3 data show survodutide normalized liver fat in 61% of patients with MASLD while reducing weight, visceral fat, and metabolic risk factors.

ADA 2026 data show survodutide cut visceral fat by 34% and liver fat by 63%, suggesting metabolic benefits beyond weight loss in phase 3 trials.

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.

After FDA approval for children 6 and older, ADA data show inhaled insulin's safety and satisfaction benefits, but clinician awareness remains a key barrier.

Covering delgocitinib for chronic hand eczema could save a 1M-member plan $88M over 3 years, driven by lower drug costs than off-label therapies.

The approval of a new oral postexposure prophylaxis for COVID-19 marks a significant advancement in the disease's prevention landscape.

Phase 3 SUNRISE data show tezepelumab reduced oral corticosteroid use while maintaining asthma control in severe asthma.

Psoriasis may share a tryptophan-driven metabolic pathway behind depression, arthritis, and metabolic syndrome.

Invited commentaries on the CORAL trial praise nalbuphine's potential in IPF cough while raising questions about safety and durability.

The 2026 EHA Congress, convening in Stockholm next week, will bring the global hematology community together for 4 days of science, debate, and discovery.

CLL’s intrinsic immune dysfunction spans humoral, cellular, and innate defects, persisting even with targeted therapy.

FDA decisions in May 2026 included 5 major oncology approvals, including first-in-class therapies for breast cancer, AML, MCL, and NMIBC.

Late-breaker data from EASL Congress 2026 mark a pivotal moment in chronic hepatitis B research.

Men and urban minority patients with early-onset CRC face elevated CVD death risk, highlighting gaps in survivorship care and research, Meng-Han Tsai, PhD, said.

Structural racism was associated with wider NSCLC survival disparities, with a 10-point Black-White gap in highly segregated counties.

MASH cirrhosis treatment, fibrosis reversal, and population screening were cited by experts as hepatology's biggest gaps.

In this real-world study of patients with type 2 diabetes, treatment with semaglutide resulted in greater reductions in body weight and hemoglobin A1c than dulaglutide.

Acoramidis treatment sustained reductions in all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months.

A post hoc analysis found that worsening symptoms, declining quality of life, and rising NT-proBNP levels frequently precede sudden death in HFmrEF/HFpEF.

Advanced therapies must expand into community settings to improve access and address health equity gaps.

Manufacturing questions delay review of dexmethylphenidate candidate; no safety or efficacy concerns raised.

James F. Howard, MD, discusses what he believes will be the next steps in treating myasthenia gravis.

How awareness, screening, and team-based care help catch chronic kidney disease early and cut heart risk with new protective medicines.

Socioeconomic, racial, and institutional factors significantly affect treatment access and patient outcomes in Guillain-Barré syndrome, despite standardized care guidelines in the US.